Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Sirona Biochem Corp V.SBM

Alternate Symbol(s):  SRBCF

Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France with a specialization in the stabilization of carbohydrate molecules. The Company is exploring the areas of diabetes, dyschromia, anti-aging, anti-cellulite and antiviral therapies and relies on a business model of licensing patents to large organizations in return for up-front and milestone payments as well as royalties. Its two most advanced programs are the cosmetic skin lightener and diabetes drug. The Company's TFC-1067 is for the treatment of Dyschromia (Dark spots on the skin). GlycoProteMim is a novel anti-aging compound. GlycoProteMim is based on the naturally occurring glycoproteins found in Antarctic fish, known to protect them against environmental stressors. It is focused on three current antiviral categories: Neuraminidase Inhibitors, Nucleoside Analogs and Iminosugars. Its wholly owned subsidiary is TFChem S.A.R.L.


TSXV:SBM - Post by User

Comment by theteddyfactoron Jun 20, 2022 11:05am
194 Views
Post# 34768780

RE:RE:RE:Senior VP from Bayer as Board Member

RE:RE:RE:Senior VP from Bayer as Board MemberReal change would mean , board member, CEO, CFO..

I thing and I might be wrong. An advisor to the board, can be tossed aside as fast as he was hired. I am sure any new mangment  and or board member brought to the table  would of kept the share price synergy positive. No doubt Dr. Wolfgang would be such based on his bio.

But as Transperance says, having tnew membesr to to significant positions with Adequate goverance, who can make changes , would make it interesting . Another advisor seems like a cosmetic position leading back to many complaints on Sttockhouse having a confidence issue , logically giving reasona decline in the share price even when this news was marketed well.

I hope this is not an end to the positive gains.
 
 
<< Previous
Bullboard Posts
Next >>